We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
Read MoreHide Full Article
Key Takeaways
HROW shares rose after relaunching Verkazia, an FDA-approved eye drop for vernal keratoconjunctivitis.
Harrow relaunched Verkazia to improve supply, access and support for physician prescribing.
Verkazia is the first FDA-approved nonsteroidal therapy specifically indicated for VKC.
Shares of Harrow (HROW - Free Report) rose 7.3% on June 10, 2026, after the company relaunched Verkazia (cyclosporine ophthalmic emulsion) 0.1% in the United States. Verkazia is an FDA-approved steroid-sparing eye drop for the treatment of patients with vernal keratoconjunctivitis (VKC).
VKC is a chronic inflammatory eye disease that primarily affects children and can lead to severe symptoms, including itching, pain, light sensitivity and corneal damage. The condition often persists for years, significantly affecting quality of life, daily activities and development, while treatment options have historically been limited, especially for pediatric patients.
Year to date, Harrow shares have lost 26.8% compared with the industry’s 9.9% decline.
Image Source: Zacks Investment Research
Rationale Behind the Relaunching of HROW’s Verkazia
The relaunch of Verkazia aimed to address longstanding access and supply challenges that have limited the availability of this FDA-approved therapy for patients with VKC. Despite the drug's established clinical efficacy, many patients have faced difficulties obtaining consistent treatment. Harrow reintroduced Verkazia to ensure a dependable supply chain, improve patient access and support physicians in prescribing a proven steroid-sparing therapy for a disease that remains significantly underdiagnosed and underserved, particularly among pediatric patients requiring long-term management.
Management described Verkazia as the second of three priority products that Harrow is commercializing as part of its broader ophthalmology growth plan.
In pediatric VKC, antihistamines often fail to control the underlying inflammation, forcing reliance on corticosteroids as the primary treatment despite their long-term risks. Verkazia was developed to address this unmet need. As the first FDA-approved nonsteroidal therapy specifically indicated for VKC, it offers a targeted approach to controlling the disease's underlying inflammatory mechanisms.
Over the past 30 days, earnings estimates for Indivior Pharmaceuticals were unchanged at $4.05 per share for 2026 and $4.27 for 2027. INDV shares have risen 6.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in the trailing four quarters, the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have gained 89.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.
Over the past 30 days, earnings estimates for Immunocore’s 2026 were unchanged at 6 cents per share for 2026 and 87 cents for 2027. IMCR shares have lost 19.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
Key Takeaways
Shares of Harrow (HROW - Free Report) rose 7.3% on June 10, 2026, after the company relaunched Verkazia (cyclosporine ophthalmic emulsion) 0.1% in the United States. Verkazia is an FDA-approved steroid-sparing eye drop for the treatment of patients with vernal keratoconjunctivitis (VKC).
VKC is a chronic inflammatory eye disease that primarily affects children and can lead to severe symptoms, including itching, pain, light sensitivity and corneal damage. The condition often persists for years, significantly affecting quality of life, daily activities and development, while treatment options have historically been limited, especially for pediatric patients.
Year to date, Harrow shares have lost 26.8% compared with the industry’s 9.9% decline.
Image Source: Zacks Investment Research
Rationale Behind the Relaunching of HROW’s Verkazia
The relaunch of Verkazia aimed to address longstanding access and supply challenges that have limited the availability of this FDA-approved therapy for patients with VKC. Despite the drug's established clinical efficacy, many patients have faced difficulties obtaining consistent treatment. Harrow reintroduced Verkazia to ensure a dependable supply chain, improve patient access and support physicians in prescribing a proven steroid-sparing therapy for a disease that remains significantly underdiagnosed and underserved, particularly among pediatric patients requiring long-term management.
Management described Verkazia as the second of three priority products that Harrow is commercializing as part of its broader ophthalmology growth plan.
In pediatric VKC, antihistamines often fail to control the underlying inflammation, forcing reliance on corticosteroids as the primary treatment despite their long-term risks. Verkazia was developed to address this unmet need. As the first FDA-approved nonsteroidal therapy specifically indicated for VKC, it offers a targeted approach to controlling the disease's underlying inflammatory mechanisms.
HROW’s Zacks Rank & Stocks to Consider
Harrow currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings estimates for Indivior Pharmaceuticals were unchanged at $4.05 per share for 2026 and $4.27 for 2027. INDV shares have risen 6.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in the trailing four quarters, the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have gained 89.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.
Over the past 30 days, earnings estimates for Immunocore’s 2026 were unchanged at 6 cents per share for 2026 and 87 cents for 2027. IMCR shares have lost 19.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.